$CVKD 8-K SEC Filings

Filed On	Filing
07 Oct 2026	8-K: Regulation FD Disclosure; Other Events CADRENAL THERAPEUTICS RETAINS TUNGSTEN ADVISORS TO LEAD FORMAL STRATEGIC PROCESS TO MAXIMIZE VALUE OF ITS ORPHAN THROMBO-INFLAMMATORY THERAPEUTICS
29 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders WHEREAS, the Board of Directors (the “Board”) of Cadrenal Therapeutics, Inc. (the “Company”) heretofore established the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan, as amended (the “Plan”); and
31 Aug 2026	8-K: Regulation FD Disclosure; Other Events
13 Aug 2026	8-K: Results of Operations and Financial Condition
21 Jul 2026	8-K: Regulation FD Disclosure; Other Events
17 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
10 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
01 Jul 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
29 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation
18 Jun 2026	8-K: Regulation FD Disclosure; Other Events
03 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation
07 May 2026	8-K: Results of Operations and Financial Condition
30 Apr 2026	8-K: Regulation FD Disclosure; Other Events
01 Apr 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
31 Mar 2026	8-K: Results of Operations and Financial Condition
12 Mar 2026	8-K: Regulation FD Disclosure; Other Events
24 Feb 2026	8-K: Other Events
23 Dec 2025	8-K: Other Events
16 Dec 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
11 Dec 2025	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Comments